Gandham, Anoohya
Gregori, Giulia
Johansson, Lisa
Larsson, Berit A. M.
Johansson, Helena
Harvey, Nicholas C.
Vandenput, Liesbeth
McCloskey, Eugene
Kanis, John A.
Litsne, Henrik
Axelsson, Kristian
Lorentzon, Mattias http://orcid.org/0000-0003-0749-1431
Funding for this research was provided by:
Vetenskapsrådet
Sahlgrenska University Hospitals Research Foundations
University of Gothenburg
Article History
Received: 1 March 2024
Accepted: 15 July 2024
First Online: 6 August 2024
Declarations
:
: M. Lorentzon has received lecture fees from Amgen, Astellas, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Parexel International, and Consilient Health. J. A. Kanis is a director of Osteoporosis Research Ltd. N Harvey has received consultancy, lecture fees, and honoraria from the Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, UCB, Kyowa Kirin, Consilient Healthcare, Theramex, Radius Health, and Internis Pharma. E. McCloskey has received research funding, consultancy, lecture fees, and/or honoraria from Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, UCB, Unilever, and Warner Chilcott. Dr Axelsson has received lecture fees from Lilly, Meda/Mylan, and Amgen. Dr. L Johansson has received lecture fees from UCB. Dr. B Larsson has received lecture fees from Boeringer-Ingelheim and consulting fees from Praktisk Medicin. All other authors have no conflicts of interest.